Advertisement

Topics

Latest "Sopherion Therapeutics, LLC" News Stories

11:16 EDT 17th October 2017 | BioPortfolio

Here are the most relevant search results for "Sopherion Therapeutics, LLC" found in our extensive news archives from over 250 global news sources.

More Information about Sopherion Therapeutics, LLC on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Sopherion Therapeutics, LLC for you to read. Along with our medical data and news we also list Sopherion Therapeutics, LLC Clinical Trials, which are updated daily. BioPortfolio also has a large database of Sopherion Therapeutics, LLC Companies for you to search.

Showing "Sopherion Therapeutics" News Articles 1–25 of 8,100+

Tuesday 17th October 2017

M3 Biotechnology Launches Clinical Trials for Alzheimer’s Disease Drug Focused on Restoring Lost Connections in the Brain

A six-year-old biotech company at the leading edge of regenerative medicine is bringing a therapy for Alzheimer’s to Phase I clinical trials that is expected to slow or stop disease progression as indicated by pre-clinical studies, announced M3 CEO Leen Kawas. “The launch of our first-in-human clinical trials is a significant step toward reali...


Saniona AB: Saniona's Partner Cadent Therapeutics Receives Milestone from Novartis

PRESS RELEASE October 17, 2017 Saniona, a leading biotech company in the field of ion channels, today announced that its collaboration partner, Cadent Therapeutics (former Luc Therapeutics), has earned a milestone payment from Novartis for the initiation of a Phase 1 clinical study for one of its pipeline programs. "We wish to congratulate Cadent with this important milestone i...

Dystonia Global Clinical Trials Review, H2, 2017 [Report Updated: 31072017] Prices from USD $2500

Dystonia Global Clinical Trials Review, H2, 2017SummaryGlobalData's clinical trial report, Dystonia Global Clinical Trials Review, H2, 2017" provides an overview of Dystonia clinical trials scenario. This report provides top line data relating to the clinical trials on Dystonia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. T...


ProMIS Neurosciences Lead Product Candidate, PMN310, Shows Desired Target Binding Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies for Alzheimer's Disease

Narrated presentation of results available on ProMIS website TORONTO and CAMBRIDGE, Mass., Oct. 17, 2017 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced that its lead product candidate for Alzheimer's disease, PMN310, showed the desired binding p...

Allurion Technologies Appoints Four Distinguished Board Members; Secures Term Loan from Silicon Valley Bank

Michael Davin, Gail Zauder, Todd Zavodnick and Krishna Gupta bring a wealth of experience to the growing Allurion Technologies team Silicon Valley Bank term loan further strengthens Allurion’s balance sheet following Series C financing Allurion Technologies, maker of the Elipse® Balloon – the world’s first and only procedureless...

Abeona to receive grants from Sanfilippo foundations for development of gene therapies

A clinical-stage biopharmaceutical company, Abeona Therapeutics, has announced a collaborative agreement between nine Sanfilippo foundations to provide grants for the advancement of its gene therapy programme.

Gilead Sciences Announces Promotion of Alessandro Riva to Executive Vice President, Oncology Therapeutics

Gilead Sciences, Inc. (Nasdaq: GILD) announced today the promotion of Alessandro Riva, MD, to Executive Vice President, Oncology Therapeutics, with responsibility for Gilead’s hematology and oncology programs, including cell therapy research and development. Dr. Riva will become a member of Gilead’s senior leadership team. Dr. Riva joined Gile...

Concentric Analgesics Names Thomas B. King to Board of Directors

Company Launches New Program in Osteoarthritis Pain Concentric Analgesics, Inc., a development-stage biopharmaceutical pain company, announced today that it has appointed Thomas B. King to its Board of Directors. Mr. King brings nearly 40 years of leadership experience building, operating and selling multiple biopharmaceutical businesses. ...

Gemini Therapeutics Announces $42.5 Million Series A Financing to Develop Precision Therapeutics in Ophthalmology and Rare Genetic Diseases

Founded to translate discoveries in age-related macular degeneration (AMD) genetics into precision therapeutics for patients Broad pipeline of first-in-class therapeutic candidates with potential in ophthalmology and rare complement-mediated genetic diseases Founders and advisors include leading experts in retin...

Takeda and HemoShear Therapeutics Enter into Exclusive Drug Discovery Partnership in Liver Diseases

Deal combines HemoShear’s REVEAL-Tx™ platform with Takeda’s drug discovery and development capabilities Takeda Pharmaceutical Company Limited (TSE: 4502) and HemoShear Therapeutics, LLC,

Cerevance Licenses Human Brain Tissue Profiling Technology from The Rockefeller University

Cerevance, a drug discovery and development company focused on brain diseases, today announced that it has signed an agreement with The Rockefeller University to license a novel technology for profiling specific cell populations in human brain tissue. Cerevance is exercising an option agreement it previously signed with Rockefeller to license the technolog...

Promising data for Sanofi, Regeneron’s dupilumab

Sanofi and Regeneron have unveiled positive results from a mid-stage study exploring the potential of the biologic dupilumab in adults with eosinophilic esophagitis, and also signed a deal with Aimmune Therapeutics to test an experimental peanut allergy therapy.

Peanut allergies? There’s a clinical trial looking to fix that

Aimmune Therapeutics, a biotech company developing treatments for food allergies, announced that it has entered into a clinical trial collaboration with Regeneron and Sanofi to develop its AR101 treatment for peanut allergies. The clinical trial will see AR101 partnered with inflammation-suppressing therapy, Dupixent, in a Phase 2 trial. The trial will determine whether patients receiving the two ...

Checkpoint Therapeutics Inc CKPT Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 12092017] Prices from USD $250

SummaryCheckpoint Therapeutics Inc Checkpoint Therapeutics, a subsidiary of Fortress Biotech Inc, is a biopharmaceutical company that acquires, develops and commercializes nonchemotherapy and immune enhanced combination treatments against solid tumors. The company develops oral anticancer therapies. Its pipeline includes a portfolio of human immunooncology targeted antibodies and various inhibitor...

Ebb Therapeutics™ selects The Copley Consulting Group To Implement Infor CloudSuite Industrial (SyteLine)™ Solution

The CloudSuite Industrial solution will enable Ebb Therapeutics to scale operations rapidly and meet the expanding customer and market demands with an exceptionally high level of quality. WOBURN, Mass. (PRWEB) October 17, 2017 Ebb Therapeutics, the medical device innovator of Ebb Insomnia Therapy, has selected The Copley Consulting Group to facilitate and deploy Infor’s CloudSuite Industrial (S...

Regeneron, Sanofi Cite Progress in Pursuing Eosinophilic Esophagitis Indication for Dupixent

Regeneron and Sanofi today reported progress toward adding new food allergy indications for their marketed drug Dupixent ® (dupilumab) with announcements of successful Phase II results in adults with active moderate-to-severe eosinophilic esophagitis, and the launch of a Phase II study with Aimmune Therapeutics assessing the treatment in peanut-allergic patients. At the World Congress of ...

Aimmune Therapeutics And DBV Technologies: 2 Different Approaches To Peanut Allergy That Are Likely To Eventually Become Commercially Successful

Esophageal Diseases Global Clinical Trials Review, H2, 2017 [Report Updated: 11082017] Prices from USD $2500

Esophageal Diseases Global Clinical Trials Review, H2, 2017SummaryGlobalData's clinical trial report, Esophageal Diseases Global Clinical Trials Review, H2, 2017" provides an overview of Esophageal Diseases clinical trials scenario. This report provides top line data relating to the clinical trials on Esophageal Diseases. Report includes an overview of trial numbers and their average enrollment in...

Asia Executives To Watch: Pfizer Japan New President, Novo Nordisk China GM

Pfizer appoints new leadership in Japan amid sluggish growth. Top executive changes also made at Novo Nordisk and Stryker in...   

Monday 16th October 2017

Spark Therapeutics Ignites Excitement Over Unanimous Adcom Panel Vote

Abeona Therapeutics Announces Pricing of Public Offering of Common Stock

NEW YORK and CLEVELAND, Oct. 16, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell therapies for life-threatening rare diseases, today announced the pricing of an underwritten public offering of five million shares of common stock at a public offering price of $16.00 per share. The gr...

Voyager Therapeutics Announces New Data Presentations at the Congress of the European Society of Gene and Cell Therapy

New data with novel AAV gene therapy capsids demonstrate widespread gene transfer to the brain and spinal cord of non-human primates after a single intravenous administration Additional studies at Voyager are underway in non-human primates with these novel capsids and other novel AAV vectors focusing on regions critical for the treatment of ALS, Friedreich’s ataxia, as well as brain regions...

The Alliance for Regenerative Medicine Releases Agenda for Fifth Annual 2017 European Advanced Therapies Investor Day

LONDON, UNITED KINGDOM and WASHINGTON, DC -- (Marketwired) -- 10/17/17 -- The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the cell and gene therapy and broader regenerative medicine sector, along with co-hosts UK BioIndustry Association (BIA) and the Cell and Gene Therapy Catapult, releases the agenda for its annual European Advanced Therapies In...

Crown Bioscience to Showcase Scientific Expertise in Preclinical Evaluation of Investigational Cancer Compounds at the American Association for Cancer Research’s International Conference on Molecular Targets and Cancer Therapeutics

SANTA CLARA, Calif., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, will showcase their scientific expertise at this year’s American...

Dyspnea Global Clinical Trials Review, H2, 2017 [Report Updated: 31072017] Prices from USD $2500

Dyspnea Global Clinical Trials Review, H2, 2017SummaryGlobalData's clinical trial report, Dyspnea Global Clinical Trials Review, H2, 2017" provides an overview of Dyspnea clinical trials scenario. This report provides top line data relating to the clinical trials on Dyspnea. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The r...


Quick Search
Advertisement
 

News Quicklinks